Information Provided By:
Fly News Breaks for February 3, 2016
RHHBY, PACB
Feb 3, 2016 | 14:32 EDT
Cantor Fitzgerald analyst Bryan Brokmeier believes Roche (RHHBY) may have approached Pacific Biosciences (PACB) to discuss an acquisition, as reported by Reuters, but he thinks that the two companies are too far apart on price and an acquisition most likely won't occur until the second half of this year or later. However, he believes Pacific Biosciences shares currently trade at a compelling valuation and recommends that investors buy on any dips. Brokmeier keeps a Buy rating and $18 price target on the stock.
News For PACB;RHHBY From the Last 2 Days
RHHBY
RHHBY
Apr 24, 2024 | 06:30 EDT
PACB
PACB
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.